Clinical cancer research, 2018-05, Vol.24 (10), p.2241-2250
2018
Details
- Autor(en) / Beteiligte
- Titel
- Biomarker-Based Therapy in Pancreatic Ductal Adenocarcinoma: An Emerging Reality?
- Ist Teil von
- Clinical cancer research, 2018-05, Vol.24 (10), p.2241-2250
- Ort / Verlag
- United States: American Association for Cancer Research Inc
- Erscheinungsjahr
- 2018
- Link zum Volltext
- Quelle
- Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
- Beschreibungen/Notizen
- Over the last decade, many of the major solid organ cancers have seen improvements in survival due to development of novel therapeutics and corresponding biomarkers that predict treatment efficacy or resistance. In contrast, favorable outcomes remain challenging in pancreatic ductal adenocarcinoma (PDAC), in part related to the lack of validated biomarkers for patient and treatment selection and thus optimal clinical decision-making. Increasingly, however, therapeutic development for PDAC is accompanied by bioassays to evaluate response and to study mechanism of actions with a corresponding increase in the number of trials in mid to late stage with integrated biomarkers. In addition, blood-based biomarkers that provide a measure of disease activity and allow for minimally invasive tumor analyses are emerging, including circulating tumor DNA, exosomes, and circulating tumor cells. In this article, we review potential biomarkers for currently approved therapies as well as emerging biomarkers for therapeutics under development. .
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1078-0432eISSN: 1557-3265DOI: 10.1158/1078-0432.ccr-16-3169Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5955785
- Format
- –
- Schlagworte
- Adenocarcinoma, Animals, Antineoplastic Agents, Immunological - pharmacology, Antineoplastic Agents, Immunological - therapeutic use, Antineoplastic Combined Chemotherapy Protocols - adverse effects, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Bioassays, Biomarkers, Biomarkers, Tumor, Cancer-Associated Fibroblasts - drug effects, Cancer-Associated Fibroblasts - metabolism, Carcinoma, Pancreatic Ductal - diagnosis, Carcinoma, Pancreatic Ductal - etiology, Carcinoma, Pancreatic Ductal - metabolism, Carcinoma, Pancreatic Ductal - therapy, Clinical trials, Combined Modality Therapy, Decision making, Deoxyribonucleic acid, DNA, Drug development, Drug Resistance, Neoplasm, Exosomes, Humans, Immunotherapy, Induction Chemotherapy, Metabolic Networks and Pathways - drug effects, Molecular Targeted Therapy, Pancreas, Pancreatic Neoplasms, Pancreatic Neoplasms - diagnosis, Pancreatic Neoplasms - etiology, Pancreatic Neoplasms - metabolism, Pancreatic Neoplasms - therapy, Protein Kinase Inhibitors - pharmacology, Protein Kinase Inhibitors - therapeutic use, Treatment Outcome, Tumor cells, Tumors